Explore the words cloud of the InTheMLLrBALL project. It provides you a very rough idea of what is the project "InTheMLLrBALL" about.
The following table provides information about the project.
Coordinator |
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Organization address contact info |
Coordinator Country | Spain [ES] |
Total cost | 158˙121 € |
EC max contribution | 158˙121 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2017 |
Funding Scheme | MSCA-IF-EF-ST |
Starting year | 2018 |
Duration (year-month-day) | from 2018-04-01 to 2020-03-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS | ES (BARCELONA) | coordinator | 158˙121.00 |
B-cell acute lymphoblastic leukemia (B-ALL) is the commonest cancer in children and B-ALL with mixed-lineage leukemia rearrangements (MLLr) has a particularly dismal prognosis compared with other B-ALLs. Many MLLrB-ALL patients are refractory to chemotherapy and eventually relapse. Thus, MLLrB-ALL remains clinically challenging. Adoptive transfer of T cells engineered to express artificial chimeric antigen (Ag) receptors (CARs) targeting tumor cell surface-specific Ag is an exciting new approach for cancer immunotherapy. Clinical trials in patients with advanced B-ALL treated with CAR-T cells against CD19 have shown impressive disease remission; however relapse still occurs with loss of CD19. Importantly, the B-ALL patients who have not responded to CD19 CAR-T cells were mainly those carrying MLLr. A strategy to offset tumor Ag-loss relapse is to modify T cells with one CAR molecule containing two different binding domains in tandem (bispecific CAR). By using both in vitro and in vivo approaches, I plan to improve CD19 CAR-T cell therapy for MLLrB-ALL by i)developing a novel bispecific CD19/NG2 CAR, which we expect will reduce single-Ag immune pressure, and ii)through the combination of CD19 CAR-T cell therapy with P-D1/PD-L1 blockade. How to achieve a long-term persistence of CAR-T cells in the host still remains a major challenge in adoptive T cell immunotherapy, and therefore understanding the interplay between T cells, MLLrB-ALL blasts and mesenchymal stromal cells/stroma is fundamental to improve the efficiency of this immunotherapy. We will thus address in vitro and in vivo the contribution of the leukemia microenvironment to CAR-T cell efficacy, as a potential tumor microenvironment (PD1/PD1L)-mediated indirect mechanism of immune escape to CAR T-cells. This cutting-edge proposal will increase my scientific potential and I will be benefited with the complementary/leadership training activities already planned to reach in a near future an independent position.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INTHEMLLRBALL" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "INTHEMLLRBALL" are provided by the European Opendata Portal: CORDIS opendata.